Get started
Author

Jesus Corral Jaime

Observed names: J. Corral Jaime, J.C. Jaime, Jaime, Jesus Corral, Jesús Corral Jaime, Jesús Corral-Jaime
Observed institutions: Universidad Complutense de Madrid, University Medical Center Groningen, Institute of Cancer Research, University of Groningen, Heidelberg University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University Hospital Heidelberg, Spanish National Cancer Research Centre, Royal Marsden Hospital, German Center for Lung Research, Clinica Universidad de Navarra, LungenClinic Grosshansdorf, Hospital Universitario Virgen del Rocío, Hospital Universitario de Jerez, Universidad de Navarra
ORCID: 0000-0003-4377-2871
Observed ORCID: 0000-0003-4377-2871
OpenAlex ID: A5107984737
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
2017 · David P. Carbone, Martin Reck, et al. · New England Journal of Medicine · 2,652
PDF
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
2018 · Marina Chiara Garassino, Byoung-Chul Cho, et al. · The Lancet Oncology · 590
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
2019 · Taofeek K. Owonikoko, Huifeng Niu, et al. · Journal of Thoracic Oncology · 163
PDF
COVID-XNet: A Custom Deep Learning System to Diagnose and Locate COVID-19 in Chest X-ray Images
2020 · Lourdes Duran-Lopez, Juan Pedro Dominguez-Morales, et al. · Applied Sciences · 92
PDF
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
2020 · Marina Chiara Garassino, Byoung-Chul Cho, et al. · Lung Cancer · 59
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
2017 · Thomas Wehler, Michael Thomas, et al. · Lung Cancer · 54
PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
2012 · Luis Paz-Ares, Filippo De Marinis, et al. · Journal of Clinical Oncology · 53
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients
2023 · Benito Farina, Ana Delia Ramos Guerra, et al. · Journal of Translational Medicine · 51
PDF
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
2010 · Luis G Paz-Ares, Sedat Altug, et al. · BMC Cancer · 36
PDF
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
2025 · James Chih-Hsin Yang, Mengzhao Wang, et al. · Journal of Clinical Oncology · 35
SEOM clinical guidelines for anaemia treatment in cancer patients (2020)
2021 · Y. Escobar Álvarez, R. de las Peñas Bataller, et al. · Clinical & Translational Oncology · 34
Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
2017 · Tony Mok, Ying Cheng, et al. · Journal of Clinical Oncology · 33
Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).
2018 · Kevin J. Harrington, Anthony Hee Kong, et al. · Journal of Clinical Oncology · 25
PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
2012 · Luis Paz-Ares, Filippo De Marinis, et al. · Journal of Clinical Oncology · 20
Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.
2016 · David Michael Hyman, Ben Tran, et al. · Journal of Clinical Oncology · 19
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib Results
2017 · Martin Reck, Edward B. Garon, et al. · Clinical Lung Cancer · 18
Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).
2014 · Cristina Cruz Zambrano, Martin H. Schuler, et al. · Journal of Clinical Oncology · 15
Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.
2018 · Tony Mok, Ying Cheng, et al. · Journal of Clinical Oncology · 11
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non–Small-Cell Lung Cancer
2016 · Edward B. Garon, Martin Reck, et al. · Clinical Lung Cancer · 10
Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging.
2012 · Jesus Corral Jaime, Anne Mary Young, et al. · Journal of Clinical Oncology · 10
Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
2017 · Tony Mok, Ying Cheng, et al. · Journal of Clinical Oncology · 9
Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001).
2025 · Kartik Sehgal, Jesus Corral Jaime, et al. · Journal of Clinical Oncology · 8
Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).
2014 · Jordi Rodon Ahnert, Martin H. Schuler, et al. · Journal of Clinical Oncology · 7
1260P Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study
2024 · L. Doucet, L. Greillier, et al. · Annals of Oncology · 3
Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance
2019 · S. Michels, B. Massuti Sureda, et al. · Annals of Oncology · 2
Works count: 45
Citation count: 4,049
H-index: 17
I10-index: 21
Year
Topic
Type